Shilpa Medicare directed to to pay damage to Celltrion
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Lays foundation stone of NIPER Hyderabad and NIPER Raebareli
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
He is also inducted as a member of the management council and senior management personnel of the company
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Star Health's convenient claims process, valued added offerings like free telemedicine consultations with expert doctors
Subscribe To Our Newsletter & Stay Updated